1. Association of busulfan area under the curve with veno-occlusive disease following BMT;Dix;Bone Marrow Transplant,1996
2. Test dose and traditional first dose therapeutic drug monitoring for busulfan (Bu) fail to accurately predict steady-state systemic exposure in allogeneic bone marrow transplantation patients;Lindley;Proc Am Soc Clin Oncol,2001
3. Target dose adjustment of busulfan using pharmacokinetic parameters in pediatric patients undergoing bone marrow transplantation for malignancy or genetic disease [abstract 635];Bolinger;Blood,1999
4. Busulfan disposition;Grochow;Semin Oncol,1993
5. Busulfan bioavailability;Hassan;Blood,1994